



## SEQUENCE LISTING

<110> UEMURA, Hidetoshi  
OKUI, Akira  
KOMINAMI, Katsuya  
YAMAGUCHI, Nozomi  
MITSUI, Shinichi

<120> NOVEL SERINE PROTEASE BSSP5

<130> UEMURA=5

<140> 09/856,319  
<141> 2001-05-21

<150> JP 10/347806  
<151> 1998-11-20

<150> PCT JP99/06473  
<151> 1999-11-19

<160> 32

<170> PatentIn version 3.1

<210> 1  
<211> 1149  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (11)..(802)  
<223>

<220>  
<221> mat\_peptide  
<222> (110)..()  
<223>

<400> 1  
atctgccacg atg ttg ctg ctc agc ctg acc cta agc ctg gtt ctc ctc 49  
Met Leu Leu Leu Ser Leu Thr Leu Ser Leu Val Leu Leu  
-30 -25

ggc tcc tcc tgg ggc tgc ggc att cct gcc atc aaa ccg gca ctg agc 97  
Gly Ser Ser Trp Gly Cys Gly Ile Pro Ala Ile Lys Pro Ala Leu Ser  
-20 -15 -10 -5

tcc agc cag agg att gtc aac ggg gag aat gca gtg ttg ggc tcc tgg 145  
Phe Ser Gln Arg Ile Val Asn Gly Glu Asn Ala Val Leu Gly Ser Trp  
-1 1 5 10

ccc tgg cag gtg tcc ctg cag gac agc agc ggc ttc cac ttc tgc ggt 193  
Pro Trp Gln Val Ser Leu Gln Asp Ser Ser Gly Phe His Phe Cys Gly  
15 20 25

ggt tct ctc atc agc cag tcc tgg gtc act gct gcc cac tgc aat 241  
Gly Ser Leu Ile Ser Gln Ser Trp Val Val Thr Ala Ala His Cys Asn  
30 35 40

RECEIVED  
MAR 14 2002  
TECH CENTER 1600/2900

gtc agc cct ggc cgc cat ttt gtt gtc ctg ggc gag tat gac cga tca Val Ser Pro Gly Arg His Phe Val Val Leu Gly Glu Tyr Asp Arg Ser 45 50 55 60	289
tca aac gca gag ccc ttg cag gtt ctg tcc gtc tct cgg gcc att aca Ser Asn Ala Glu Pro Leu Gln Val Leu Ser Val Ser Arg Ala Ile Thr 65 70 75	337
cac cct agc tgg aac tct acc acc atg aac aat gac gtg acg ctg ctg His Pro Ser Trp Asn Ser Thr Thr Met Asn Asn Asp Val Thr Leu Leu 80 85 90	385
aag ctc gcc tcg cca gcc cag tac aca aca cgc atc tcg cca gtt tgc Lys Leu Ala Ser Pro Ala Gln Tyr Thr Thr Arg Ile Ser Pro Val Cys 95 100 105	433
ctg gca tcc tca aac gag gct ctg act gaa ggc ctc acg tgt gtc acc Leu Ala Ser Ser Asn Glu Ala Leu Thr Glu Gly Leu Thr Cys Val Thr 110 115 120	481
acc ggc tgg ggt cgc ctc agt ggc gtg ggc aat gtg aca cca gca cat Thr Gly Trp Gly Arg Leu Ser Gly Val Gly Asn Val Thr Pro Ala His 125 130 135 140	529
ctg cag cag gtg gct ttg ccc ctg gtc act gtg aat cag tgc cgg cag Leu Gln Gln Val Ala Leu Pro Leu Val Thr Val Asn Gln Cys Arg Gln 145 150 155	577
tac tgg gac tca agt atc act gac tcc atg atc tgt gca ggt ggc gca Tyr Trp Asp Ser Ser Ile Thr Asp Ser Met Ile Cys Ala Gly Gly Ala 160 165 170	625
ggt gcc tcc tcg tgc cag ggt gac tcc gga ggc cct ctt gtc tgc cag Gly Ala Ser Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gln 175 180 185	673
aag gga aac aca tgg gtg ctt att ggt att gtc tcc tgg ggc acc aaa Lys Gly Asn Thr Trp Val Leu Ile Gly Ile Val Ser Trp Gly Thr Lys 190 195 200	721
aac tgc aat gtg cgc gca cct gct gtg tat act cga gtt agc aag ttc Asn Cys Asn Val Arg Ala Pro Ala Val Tyr Thr Arg Val Ser Lys Phe 205 210 215 220	769
agc acc tgg atc aac cag gtc ata gcc tac aac tgagctcacc acaggccctc Ser Thr Trp Ile Asn Gln Val Ile Ala Tyr Asn 225 230	822
cccagctcaa cccatttaaa ggacccaggc cctgtcccat catgcattca tgtctgtctt	882
cctggctcag gagaaagaag aggctgtga gggccgact ccctacttgg acttctggca	942
cagaaggggc tgagtgactc cttgagtagc agtggctctt cctagagtag ccatgccgtg	1002
gccggggccc ccacccctcc tccagggcaa ccccttggtc ctacagcaag aagccagaac	1062
tgttggaatg aatggcagcc ctccttgag aggcagcctg tttactgaat acagaggata	1122
cgtttacaaa aaaaaaaaaaaaaaaa	1149

<210> 2  
<211> 264

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Leu Leu Leu Ser Leu Thr Leu Ser Leu Val Leu Leu Gly Ser Ser  
-30 -25 -20

Trp Gly Cys Gly Ile Pro Ala Ile Lys Pro Ala Leu Ser Phe Ser Gln  
-15 -10 -5

Arg Ile Val Asn Gly Glu Asn Ala Val Leu Gly Ser Trp Pro Trp Gln  
-1 1 5 10 15

Val Ser Leu Gln Asp Ser Ser Gly Phe His Phe Cys Gly Gly Ser Leu  
20 25 30

Ile Ser Gln Ser Trp Val Val Thr Ala Ala His Cys Asn Val Ser Pro  
35 40 45

Gly Arg His Phe Val Val Leu Gly Glu Tyr Asp Arg Ser Ser Asn Ala  
50 55 60

Glu Pro Leu Gln Val Leu Ser Val Ser Arg Ala Ile Thr His Pro Ser  
65 70 75

Trp Asn Ser Thr Thr Met Asn Asn Asp Val Thr Leu Leu Lys Leu Ala  
80 85 90 95

Ser Pro Ala Gln Tyr Thr Arg Ile Ser Pro Val Cys Leu Ala Ser  
100 105 110

Ser Asn Glu Ala Leu Thr Glu Gly Leu Thr Cys Val Thr Thr Gly Trp  
115 120 125

Gly Arg Leu Ser Gly Val Gly Asn Val Thr Pro Ala His Leu Gln Gln  
130 135 140

Val Ala Leu Pro Leu Val Thr Val Asn Gln Cys Arg Gln Tyr Trp Asp  
145 150 155

Ser Ser Ile Thr Asp Ser Met Ile Cys Ala Gly Gly Ala Gly Ala Ser  
160 165 170 175

Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gln Lys Gly Asn  
180 185 190

Thr Trp Val Leu Ile Gly Ile Val Ser Trp Gly Thr Lys Asn Cys Asn  
195 200 205

Val Arg Ala Pro Ala Val Tyr Thr Arg Val Ser Lys Phe Ser Thr Trp  
 210 215 220

Ile Asn Gln Val Ile Ala Tyr Asn  
 225 230

<210> 3  
 <211> 834  
 <212> DNA  
 <213> Mus sp.

<220>  
 <221> mat\_peptide  
 <222> (132)..()  
 <223>

<220>  
 <221> CDS  
 <222> (33)..(824)  
 <223>

<400> 3  
 gaccatctca acaccattcc ttatttgtca ca atg cta ctg ctc agc cta acc 53  
 Met Leu Leu Leu Ser Leu Thr  
 -30  
 ctt agc ctg gtc ctc ctt ggc tcc tcc tgg ggc tgt ggt gtt cct gcc 101  
 Leu Ser Leu Val Leu Leu Gly Ser Ser Trp Gly Cys Gly Val Pro Ala  
 -25 -20 -15  
 atc acg cct gca ctg agc tac aat cag aga att gtc aac ggg gag aat 149  
 Ile Thr Pro Ala Leu Ser Tyr Asn Gln Arg Ile Val Asn Gly Glu Asn  
 -10 -5 -1 1 5  
 gca gtg cca ggc tcc tgg ccc tgg cag gtg tct ctc cag gat aac acc 197  
 Ala Val Pro Gly Ser Trp Pro Trp Gln Val Ser Leu Gln Asp Asn Thr  
 10 15 20  
 ggc ttc cac ttc tgc ggt ggt tct ctc atc agt ccg aac tgg gtg gtc 245  
 Gly Phe His Phe Cys Gly Ser Leu Ile Ser Pro Asn Trp Val Val  
 25 30 35  
 acg gct gcc cac tgc caa gtc acg cct gga cgc cac ttt gtc gtt ttg 293  
 Thr Ala Ala His Cys Gln Val Thr Pro Gly Arg His Phe Val Val Leu  
 40 45 50  
 gga gaa tat gac cga tct tcc aat gct gaa cct gtg cag gtc ctc tcg 341  
 Gly Glu Tyr Asp Arg Ser Ser Asn Ala Glu Pro Val Gln Val Leu Ser  
 55 60 65 70  
 atc gca agg gcc atc aca cac cct aac tgg aac gcc aac acc atg aac 389  
 Ile Ala Arg Ala Ile Thr His Pro Asn Trp Asn Ala Asn Thr Met Asn  
 75 80 85  
 aat gac ctg act ctc ctg aag ctt gcc tcg cca gcc cggt tac aca gca 437  
 Asn Asp Leu Thr Leu Leu Lys Leu Ala Ser Pro Ala Arg Tyr Thr Ala  
 90 95 100

caa gtc tca cca gtc tgc ctg gct tcc aca aac gag gca ctg cct tcg Gln Val Ser Pro Val Cys Leu Ala Ser Thr Asn Glu Ala Leu Pro Ser 105 110 115	485
ggg ctc acc tgt gtc acc act ggc tgg ggc cga atc agt ggt gtg ggc Gly Leu Thr Cys Val Thr Gly Trp Gly Arg Ile Ser Gly Val Gly 120 125 130	533
aat gtg aca cca gct cgc ctg cag caa gtt gtt cta ccc ctg gtc act Asn Val Thr Pro Ala Arg Leu Gln Gln Val Val Leu Pro Leu Val Thr 135 140 145 150	581
gtg aat cag tgt cgg cag tac tgg ggt gca cgc att acc gat gcc atg Val Asn Gln Cys Arg Gln Tyr Trp Gly Ala Arg Ile Thr Asp Ala Met 155 160 165	629
ata tgt gca ggt ggc tca ggc gcc tcc tca tgt cag ggt gac tca gga Ile Cys Ala Gly Gly Ser Gly Ala Ser Ser Cys Gln Gly Asp Ser Gly 170 175 180	677
ggc cct ctt gtc tgc cag aag gga aac acc tgg gtg ctt att ggg att Gly Pro Leu Val Cys Gln Lys Gly Asn Thr Trp Val Leu Ile Gly Ile 185 190 195	725
gtc tcc tgg ggc act aag aac tgc aac ata caa gca ccg gcc atg tac Val Ser Trp Gly Thr Lys Asn Cys Asn Ile Gln Ala Pro Ala Met Tyr 200 205 210	773
act cgg gtc agc aag ttc agt acc tgg atc aac caa gtc atg gcc tac Thr Arg Val Ser Lys Phe Ser Thr Trp Ile Asn Gln Val Met Ala Tyr 215 220 225 230	821
aac taaactgtcc Asn	834

<210> 4  
<211> 264  
<212> PRT  
<213> Mus sp.

<400> 4

Met Leu Leu Ser Leu Thr Leu Ser Leu Val Leu Leu Gly Ser Ser  
-30 -25 -20

Trp Gly Cys Gly Val Pro Ala Ile Thr Pro Ala Leu Ser Tyr Asn Gln  
-15 -10 -5

Arg Ile Val Asn Gly Glu Asn Ala Val Pro Gly Ser Trp Pro Trp Gln  
-1 1 5 10 15

Val Ser Leu Gln Asp Asn Thr Gly Phe His Phe Cys Gly Gly Ser Leu  
20 25 30

Ile Ser Pro Asn Trp Val Val Thr Ala Ala His Cys Gln Val Thr Pro  
35 40 45

Gly Arg His Phe Val Val Leu Gly Glu Tyr Asp Arg Ser Ser Asn Ala  
 50 55 60

Glu Pro Val Gln Val Leu Ser Ile Ala Arg Ala Ile Thr His Pro Asn  
 65 70 75

Trp Asn Ala Asn Thr Met Asn Asn Asp Leu Thr Leu Leu Lys Leu Ala  
 80 85 90 95

Ser Pro Ala Arg Tyr Thr Ala Gln Val Ser Pro Val Cys Leu Ala Ser  
 100 105 110

Thr Asn Glu Ala Leu Pro Ser Gly Leu Thr Cys Val Thr Thr Gly Trp  
 115 120 125

Gly Arg Ile Ser Gly Val Gly Asn Val Thr Pro Ala Arg Leu Gln Gln  
 130 135 140

Val Val Leu Pro Leu Val Thr Val Asn Gln Cys Arg Gln Tyr Trp Gly  
 145 150 155

Ala Arg Ile Thr Asp Ala Met Ile Cys Ala Gly Gly Ser Gly Ala Ser  
 160 165 170 175

Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gln Lys Gly Asn  
 180 185 190

Thr Trp Val Leu Ile Gly Ile Val Ser Trp Gly Thr Lys Asn Cys Asn  
 195 200 205

Ile Gln Ala Pro Ala Met Tyr Thr Arg Val Ser Lys Phe Ser Thr Trp  
 210 215 220

Ile Asn Gln Val Met Ala Tyr Asn  
 225 230

<210> 5  
 <211> 99  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide to construct plasmid pSecTrypHis.

<400> 5  
 aagcttggct agcaacacca tgaatctact cctgatcctt acctttgttg ctgctgctgt 60  
 tgctgcccccc tttgacgacg atgacaagga tccgaattc 99

<210> 6  
 <211> 99  
 <212> DNA  
 <213> Artificial Sequence

<220> Designed oligonucleotide to construct plasmid pSecTrypHis.  
 <223> Designed oligonucleotide to construct plasmid pSecTrypHis.

<400> 6  
 gaattcggat cttgtcatc gtcgtcaaag gggcagcaa cagcagcgc aacaaaggta 60  
 99  
 aggatcagga ttagattcat ggtgttgcta gccaaagctt

<210> 7  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<220> Designed oligonucleotide primer to amplify neurosin-encoding sequence.  
 <223> Designed oligonucleotide primer to amplify neurosin-encoding sequence.

<400> 7  
 ttggtgcatg gcggaa 15

<210> 8  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220> Designed oligonucleotide primer to amplify neurosin-encoding sequence.  
 <223> Designed oligonucleotide primer to amplify neurosin-encoding sequence.

<400> 8  
 tcctcgagac ttggcctgaa tggtttt 27

<210> 9  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220> Designed oligonucleotide primer to amplify a portion of plasmid p  
 <223> Designed oligonucleotide primer to amplify a portion of plasmid p  
 SecTrypHis/Neurosin.

<400> 9  
 gcgctagcag atctccatga atctactcct gatcc 35

<210> 10  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence

<220> Designed oligonucleotide primer to amplify a portion of plasmid p  
 <223> Designed oligonucleotide primer to amplify a portion of plasmid p  
 SecTrypHis/Neurosin.

<400> 10	
tgaagcttgc catggaccaa cttgtcatc	29
<210> 11	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer to amplify a portion of plasmid p TrypHis.	
<400> 11	
ccaagcttca ccatcaccat caccat	26
<210> 12	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer to amplify a portion of plasmid p TrySigTag.	
<400> 12	
gcacagtcga ggctgat	17
<210> 13	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer to amplify a portion of plasmid p FBTrypSigTag.	
<400> 13	
caaatgtggt atggctg	17
<210> 14	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer to amplify conserved region of se rin proteases-encoding sequence.	
<220>	
<221> misc_feature	
<222> (9)..(9)	
<223> n is a, c, g or t.	
<220>	
<221> misc_feature	
<222> (12)..(12)	
<223> n is a, c, g or t.	

```

<400> 14
gtgctcacng cngcbcaytg                                20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer to amplify conserved region of se
rin proteases-encoding sequence.

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g or t.

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g or t.

<400> 15
ccvctrwsdc cnccnngcga                                20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for RACE for hBSSP5 (forward).

<400> 16
tgtcagccct ggccgccatt                                20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for RACE for hBSSP5 (forward).

<400> 17
gcgagtatga ccgatcatca                                20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for RACE for hBSSP5 (reverse).

<400> 18

```

cgccacctgc acagatcatg 20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer for RACE for hBSSP5 (reverse).

<400> 19  
gaatcagtgc cggcagtact 20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as hBSSP5F1 to amplify full length hBSSP5 (forward).

<400> 20  
tgccacgatg ttgctgctca 20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as hBSSP5F2 to amplify mature hBSSP5-encoding region (forward).

<400> 21  
attgtcaacg gggagaatgc 20

<210> 22  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as hBSSP5R1/E to amplify full length hBSSP5 (reverse).

<400> 22  
ggaattcggg tcttaatgg gttgagc 27

<210> 23  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as hBSSP5R4 for RT-PCR (reverse).

<400> 23	
cctggcacga ggaggcac	18
<210> 24	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer designated as mBSSP5F1 for RACE f or mBSSP5 (forward).	
<400> 24	
accatgaaca atgacacctgac	20
<210> 25	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer designated as mBSSP5F2 for RACE f or mBSSP5 (forward)	
<400> 25	
gaatcagtgt cggcagt	17
<210> 26	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer designated as mBSSP5F3 to amplify full length mBSSP5 (forward).	
<400> 26	
gaccatctca acaccattcc	20
<210> 27	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer designated as mBSSP5F mature to a mply mature mBSSP5-encoding region (forward).	
<400> 27	
attgtcaacg gggagaatgc	20
<210> 28	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Designed oligonucleotide primer designated as mBSSP5R2 for RACE f	

or mBSSP5 (reverse).

<400> 28  
atggcatcg taatgcgtgc 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as mBSSP5R3/E to amplify full length mBSSP5 (reverse).

<400> 29  
caggtgttcc cttctggca 20

<210> 30  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide primer designated as mBSSP5R3/E to amplify full length mBSSP5 (reverse).

<400> 30  
gaaattcgga cagtttagtt gtaggcc 27

*C*  
*Cmt*  
<210> 31  
<211> 117  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide to construct plasmid pTrypHis.

<400> 31  
aagcttggct agcaacacca tgaatctact cctgatcctt acctttgttg ctgctgctgt 60  
tgctgcccccc ttccaccatc accatcacca tgacgacgat gacaaggatc cgaattc 117

<210> 32  
<211> 117  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide to construct plasmid pTrypHis.

<400> 32  
gaattcggat cttgtcatc gtcgtcatgg tggatggat ggtgaaagg ggccggcaaca 60  
gcagcagcaa caaaggtaag gatcaggagt agattcatgg tggatggatc caagctt 117